Last reviewed · How we verify
Bioarginine
Bioarginine, developed by Federico II University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Bioarginine |
|---|---|
| Sponsor | Federico II University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of L-ARGinine and Liposomal Vitamin C Supplementation On Physical Performance (NA)
- Effect of Oral L-arginine 3.32 g a Day on Oxidative Stress Influencing Beta Cell Function and Insulin Resistance. (NA)
- Evaluation of the Effect of Liposomal L-Arg and Vit C Integration on Mitochondrial Function in Patients With Heart Failure (PHASE3)
- Improving Quality of Life and Daily Life Activities With Bioarginine in Patients With COPD (NA)
- Effects of L-arginine on Myocardial Energetic Efficiency and Global Longitudinal Strain (PHASE4)
- Prevention of Type 2 Diabetes Mellitus by L-Arginine in Patients With Metabolic Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bioarginine CI brief — competitive landscape report
- Bioarginine updates RSS · CI watch RSS
- Federico II University portfolio CI